View Post

CDK4/6 Inhibitors Firmly Established in HR+ Breast Cancer, OS Data Awaited

In Clinical Trials by Barbara Jacoby

By: Gina Columbus From: onclive.com The improvement in progression-free survival (PFS) that has been observed with CDK4/6 inhibitors in patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer has led to changes in clinical practice. However, physicians are still awaiting further overall survival (OS) findings that will solidify the use of these agents, said Daphne B. Stewart, MD. Thus far, …

View Post

Continuous chemotherapy improves outcomes and quality of life in advanced breast cancer

In Clinical Trials by Barbara Jacoby

Source: European Society for Medical Oncology From: eurekalert.org Continuous chemotherapy shows greater benefit in patients with advanced breast cancer by both improving survival and maintaining quality of life compared to intermittent scheduling, according to analyses of the Stop&Go study presented at the ESMO Breast Cancer Congress 2019, 2-4 May, Berlin, Germany. (1,2,3) The phase III study randomised 420 patients with …

View Post

TRIO Enrolls First Patient Into PHASE III NATALEE Clinical Trial

In Clinical Trials by Barbara Jacoby

From: ptcommunity.com Translational Research In Oncology (TRIO), in collaboration with Novartis and under the direction of Dennis Slamon, MD, PhD, TRIO Chairman/Executive Director and Director of Clinical Translational Research at the University of California, Los Angeles Jonsson Comprehensive Cancer Center, announces enrollment of the first patient into its newest clinical trial, NATALEE (New Adjuvant TriAl with LEE). NATALEE is a …

View Post

Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study

In Clinical Trials by Barbara Jacoby

By: GlobeNewswire From: nasdaq.com Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that target enrollment of 360 patients in the Oraxol Phase III clinical trial in metastatic breast cancer has been achieved on schedule. Athenex also reaffirms that top line data from …

View Post

Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses

In Clinical Trials by Barbara Jacoby

Source: Novartis From: prnewswire.com – BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor or after receiving up to one additional line of therapy1 – SOLAR-1 is the first Phase III breast cancer trial to demonstrate potential viability of using liquid biopsy to select patients …

View Post

JHL Biotech Announces First Patient Randomized in the Phase III Study of JHL1101 to Treat Diffuse Large B-Cell Lymphoma

In Clinical Trials by Barbara Jacoby

Source: JHL Biotech From: prnewswire.co.uk JHL Biotech announced today that the first patient at Beijing Cancer Hospital has been successfully randomized in the Phase III study of JHL1101 to treat diffuse large B-cell lymphoma (DLBCL). The Phase III study is a multinational, randomized, double-blind, positive-controlled, parallel group clinical study.  It compares the efficacy and safety of JHL1101 in combination with CHOP …

View Post

Fox Chase Enrolling Patients in ONC201 Multiple Myeloma Trial

In In The News by Barbara Jacoby

Oncoceutics, Inc. announced that the first patient has begun treatment in a clinical trial of the company’s lead compound, ONC201, at the Fox Chase Cancer Center (FCCC) in relapsed/refractory multiple myeloma. The Phase I/II trial, identified as NCT02863991 on www.clinicaltrials.gov, will investigate the use of ONC201 in combination with dexamethasone in adult patients with multiple myeloma who have relapsed or …

View Post

Ongoing Clinical Trial Seeks Participation from Hispanic Patients Living With Advanced Breast Cancer

In In The News by Barbara Jacoby

Phase III EMBRACA Clinical Trial Currently Enrolling Hispanic Individuals – Particularly of Mexican and Puerto Rican Descent — due to Higher Prevalence of BRCA Mutation What:     Breast cancer is the most commonly diagnosed cancer in Hispanic women and the continued leading cause of cancer death. The EMBRACA clinical trial is studying the safety and efficacy of an investigational drug, talazoparib, …

View Post

MD Anderson Begins Lymphoma Trial for Oncoceutics’ ONC201

In In The News by Barbara Jacoby

Oncoceutics, Inc. announced that patient enrollment for a clinical trial of the company’s lead compound ONC201 in non-Hodgkin’s lymphoma has started at The University of Texas MD Anderson Cancer Center (MDACC). The trial, identified as NCT02420795 on www.clinicaltrials.gov, is entitled “Phase I/II Study of Oral ONC201 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma.” The Phase I/II trial will investigate the use …

CHMP recommends EU approval of Roche’s Subcutaneous Herceptin for HER2 positive breast cancer

In In The News by Barbara Jacoby

(Menafn – M2 PRESSWIRE via COMTEX) New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients’ time Herceptin is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year Roche (six:RO)(six:ROG)(otcqx:RHHBY) is pleased to announce that the …